Navigation Links
Cysts hold clues to pancreatic cancer

Grand Rapids, Mich. (June 3, 2010) Working with researchers from the University of Michigan and Indiana University, Van Andel Research Institute (VARI) investigators have developed a method that could be used to predict whether pancreatic cysts are benign or are precursors to invasive cancer.

More pancreatic cysts are being detected due to the widespread use of high resolution abdominal imaging. These advances in early detection, when coupled with the new findings, could result in fewer deaths from pancreatic cancer, which struck more than 42,000 Americans in 2009 and killed more than 35,000, according to the National Cancer Institute.

"Because of the difficulty in detecting pancreatic cancer in its early stages, most cancers are advanced at the time of diagnosis and recur after removal of the tumor," said VARI Senior Scientific Investigator Brian Haab, Ph.D., first author of a study published in the May issue of Annals of Surgery. "The best hope for a long-term cure may be the detection and removal of these pre-cancerous cysts."

"Dr. Haab and his colleagues have sought to address a very challenging clinical management problem regarding cystic lesions of the pancreas," said Peter J. Allen, MD, FACS, a physician and researcher specializing in pancreatic, liver, and stomach cancer at Memorial Sloan-Kettering Cancer Center. "As the use of cross-sectional imaging increases, clinicians are seeing increased numbers of patients with these lesions and it will become imperative to sort out benign from pre-malignant."

The most common and deadly form of pancreatic cancer, pancreatic ductal adenocarcinomas, develops from three types of cysts. Although the most prevalent type is too small to be detected, the other two can be found using CT or ultrasound imaging and account for 10 15% of pancreatic cancers. However, current methods can only distinguish pre-cancerous cysts from those that are benign with up to 79% accuracy.

Using fluid from a variety of cyst types, researchers looked for patterns in the variations of carbohydrate structures called glycans to determine if there were any biomarkers that could more accurately distinguish between pre-cancerous and benign cysts. They found several candidates, some of which could be used in combination to determine cyst type.

"Further study will be needed to validate the clinical value of using glycan variations to differentiate cyst types, but it seems like they are more accurate than current methods," said Dr. Haab.

"(Dr. Haab's) identification of variants of MUC-1, MUC-5AC, and MUC-16 (genes) within the cyst fluid of pre-malignant lesions is exciting as our current ability to non-operatively define these lesions is limited," said Dr. Allen. "Hopefully with larger numbers of patients these results can be validated and be put into clinical use."


Contact: Joe Gavan
Van Andel Research Institute

Related medicine news :

1. Tracking PSA Test Results Over Time Gives Clues to Cancer
2. New Clues to Treating Immune System Disorders
3. New Clues to Treating an Aggressive Breast Cancer
4. Pigs Yield Clues to Cystic Fibrosis-Related Lung Disease
5. New Clues Shed Light on Sperm Function, Male Fertility
6. Ovarian cancer study offers vital clues for new therapies
7. Change in breast density over time provides clues about breast cancer risk
8. Lab that probes genetic clues to disease is poised for major expansion
9. More Clues Emerge on How HIV Infects Women
10. Scientists Find Clues to How the Body Fights Off HIV
11. New Clues to Pregnancy-Associated Breast Cancer
Post Your Comments:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: